On account of their continuing pharmacological significance azepane ring containing structures attract considerable attention in organic synthesis and drug discovery.1-2
There are several naturally occurring azepane derivatives possessing a number of biological activities. For example, azepane ring containing metabolite (-)-balanol 13 (Figure 1) showed the potency as an ATP-competitive inhibitor of the protein kinase. This natural compound has since been used as a scaffold for development of a series of analogues as potential antitumor agents.4 Presently there are 5 approved and ca. 20 experimental drugs that have the azepane substructure.5 Among them, Tolazamide 2 is an oral blood glucose lowering drug used for people with type 2 diabetes. Another azepane containing marketed drug Azelastine 3 represents an example of a potent, second-generation, selective histamine antagonist.
Noteworthy, substituted azepanes have flexible ring structures and this conformational diversity is often decisive for their bioactivity.6 Therefore, the ability to introduce specific substituents into the azepane ring to bias it to one major conformation is important for effective drug design.
Figure 1. Examples of bioactive azepane-ring containing compounds
The full list of the functionalized azepanes offered by Life Chemicals can be obtained upon request at email@example.com. Please see some representative compounds below:
- (a) Barbero, A.; Diez-Varga, A.; Pulido, F. J.; González-Ortega, A.Org. Lett. 2016, 18, 1972–1975. (b) Zhou, J.; Yeung, Y.-Y. Org. Lett. 2014, 16, 2134–2137.
- Bremner, J. B.;Samosorn, S. In Comprehensive Heterocyclic Chemistry III, Eds. Katritzky, A. R.; Ramsden, C. A.; Scriven, E. F. V.; Taylor, R. J. K. Pergamon, Oxford, 2008. Vol. 13, p. 1.
- Kulanthaivel, P.; Hallock, Y.; Boros, C.; Hamilton, S. M.; Janzen, W. P.; Ballas, L. M.; Loomis, C. R.; Jiang, J. B.; Katz, B.; Steiner, J. R.; Clardy, J. J. Am. Chem. Soc. 1993, 115, 6452.
- Breitenlechner, C. B.; Friebe, W. G.; Brunet, E.; Werner, G.; Graul, K.; Thomas, U.; Kunkele, K. P.; Schafer, W.; Gassel, M. Bossemeyer, D.; Huber, R.; Engh, R. A.; Masjost, B.; J. Med. Chem. 2005, 48, 163.
- www.drugbank.ca; accessed in March 2019.
- (a) Patel, A. R.; Liu, F. Tetrahedron 2013, 69, 744–752. (b) Patel, A. R.; Ball, G.; Hunter, L.; Liu, F. Org. Biomol.